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Abstract
Goals The objective of this study was to determine utility
of prophylactic anti-coagulation in cancer patients hospi-
talised for palliative care in a specialised centre.
Materials and methods Prospective 1:1 open randomised
study was designed. Twenty patients aged 55 to 88 years
with advanced cancer and an estimated life expectancy of
less than 6 months were assigned to either receive treatment
with 2,850/3,800 U (<70/>70 kg) of daily subcutaneous
nadroparin or no treatment. Suspicion of venous thrombo-
embolism (deep vein thrombosis and pulmonary embolism)
was confirmed by echo-Doppler examination of the lower
limbs and/or by spiral computed tomography scan of the
lungs. Bleeding episodes were recorded. Platelet count was
measured on days 7 and 14. Survival time from study entry
was determined.
Main results One venous thrombo-embolism and one major
bleeding occurred in the group receiving nadroparin, whereas
two minor bleedings occurred in the control group. At
3 months, nine of ten participants had died in the control group
vs five of ten in the group receiving nadroparin (P=0.141).
Five participants could be discharged home (P=0.141).
Conclusions Decision to administer prophylactic nadroparin
in hospitalised cancer patients under palliative care remains a
challenge. Better mobility score at admission and the
likelihood to be discharged home may be useful for practical
purposes. The observation of a potential influence of
prophylactic nadroparin on survival deserves further studies.
Keywords Anti-coagulation . Cancer . Palliative care .
Thrombosis . Bleeding
Introduction
The association between cancer and venous thrombo-embolic
disease (VTE) was first described by Trousseau 140 years ago
[26]. Cancer type and extension can facilitate VTE together
with other risk factors such as bed confinement, anti-cancer
treatments, central venous devices and advanced age [2, 6, 9,
10, 12, 19, 25, 27]. Prevalence of VTE in cancer patients
hospitalised for palliative care can be estimated at 10% [22].
Low molecular weight heparin (LMWH) is the standard
treatment for the prevention of VTE during the first weeks
after surgery, during immobilization of the lower limb and
during acute hospitalisation for congestive heart failure,
respiratory insufficiency, infection, rheumatology problems
or inflammatory bowel disease [20, 24]. LMWH therapy
has also been shown to increase survival of patients with
advanced malignancies and a life expectancy superior to
6 months [15, 17].
In palliative care for cancer patients, primary prophy-
laxis of VTE has not been proven useful despite the
presence of many risk factors in most patients. Decision to
administer VTE prophylaxis may thus depend on health
professional experience, place of care and patients’ prefer-
ences [14]. Widely prescribed in acute hospitals, VTE
prophylaxis is rarely administered in nursing homes and
even less frequently at home, although risk factors are not
different for this patient population.
The main objective of palliative care is to improve
patients’ quality of their remaining lifetime [3, 28]. In this
context, prophylactic treatments may also be justified
because anticipation of problems is one key to achieve this
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goal. Such treatments should virtually have no side effects
and should decrease the risk of unpleasant complications
while avoiding futile investigations. This is the reason why
we started the present open prospective randomised study.
Materials and methods
The studywas approved by the Ethic and Research Committee
of University Hospitals of Geneva. Consecutive cancer
patients admitted to the centre of continuous care with an
estimated life expectancy inferior to 6 months were eligible.
Objectives were to determine the occurrence of VTE, to detect
complications and to measure survival time from study entry.
Exclusion criteria
Patients with absence of judgement abilities precluding to
sign written informed consent, VTE during the past 6 months,
active bleeding, creatinine clearance <20 ml/min, thrombo-
cytopenia <50 G/l, past history of heparin thrombocytopenia,
partial thromboplastin time (PTT) >45 s, prothrombin time
(TP) <35% and concomitant anti-coagulation treatment on
admission were excluded form this study.
Randomisation procedure
Patients were randomised 1:1 with the heparin group receiving
LMWH and the control group receiving neither LMWH nor
placebo. Sets of 20 sealed envelopes were prepared by one of
us (FH) and numbered consecutively. Each envelope
contained one YES (LMWH prophylaxis) or NO (no
prophylaxis). The sequence of treatments was randomly
assigned in blocks of constant size (n=20). There were 10
YES and 10 NO in each block. Envelopes were opened by
the principal investigator (CW) to allow treatment allocation.
Treatment
Nadroparine (Fraxiparine®) was provided by the University
Hospitals of Geneva central pharmacy. Dose was 0.3 ml, i.e.
2,850 U of anti-Xa factor for patients <70 kg and 0.4 ml, i.e.
3,800 U of anti-Xa factor for patients >70 kg. Nadroparine
was administered once daily as a subcutaneous injection.
Assessed for eligibility (n= 157) 
Excluded (n= 137) 
Not meeting inclusion criteria (n= 110) 
Refused to participate (n= 12) 
Other reasons (n= 8) 
Analyzed n=10) 
Excluded from analysis (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to intervention (n=10) 
Received allocated intervention (n=10) 
Did not receive allocated intervention (n=0)
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to intervention (n=10) 
Received allocated intervention (n=10) 
Did not receive allocated intervention (n=0) 
Analyzed (n=10) 
Excluded from analysis (n=0) 
Allocation
Analysis
Follow-Up
Enrollment
Is it Randomized ?
Fig. 1 The Consort
E-Flowchart
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Additional tests
Clinical suspicion of deep vein thrombosis (DVT) indicated
the necessity for an echo-Doppler examination of the lower
limbs. Clinical suspicion of pulmonary embolism (PE) also
indicated the necessity for such test; if negative for DVT, a
spiral computed tomography (CT) scan was then requested.
Platelet count was controlled on days 7 and 14 to screen for
heparin-induced thrombocytopenia. Bleeding episodes were
recorded and blood controls made accordingly.
Statistical analysis
A two-group continuity corrected chi-square test with a
0.050 two-sided significance level would have 80% power
to detect a difference between a group 1 proportion of
0.0500 and a group 2 proportion of 0.0125 (odds ratio of
0.241) when the sample size in each group would reach
389. After 18 months, only 20 subjects could be enrolled
among 157 eligible patients. We thus decided to analyse the
results and to submit them for publication.
Table 1 Treatment allocation, tumour characteristics and outcome
Number Group Age Gender Cancer Histology Metastasis Outcome
1 Control 79 M Head and neck Squamous cell Lymph nodes Death
2 LMWH 69 F Chronic lymphocytic leukaemia Lymph nodes Home
3 Control 71 F Breast Adeno-carcinoma Liver, bone Death
4 Control 65 M Head and neck Squamous cell Bone Death
5 Control 74 F Breast Adeno-carcinoma Liver, bone Death
6 LMWH 78 F Rectum Adeno-carcinoma Liver, lung, peritoneum Death
7 LMWH 88 F Lung Squamous cell Lung Home
8 LMWH 63 F Breast Adeno-carcinoma Liver, bone, lung Home
9 LMWH 84 M Lung Adeno-carcinoma Lung Home
10 Control 81 F Pancreas Adeno-carcinoma Liver Death
11 LMWH 67 M Rectum Adeno-carcinoma Liver Death
12 LMWH 55 M Stomach Adeno-carcinoma Liver Death
13 Control 79 M Head and neck lung Squamous cell Brain Death
14 Control 61 F Lung Small cell Brain, liver, lung Death
15 LMWH 84 F Ovary Adeno-carcinoma Peritoneum Death
16 LMWH 56 F Pancreas Adeno-carcinoma Lung Death
17 LMWH 83 M Stomach Adeno-carcinoma Liver Home
18 Control 67 M Lung Squamous cell Brain Home
19 Control 64 F Breast Adeno-carcinoma Brain Death
20 Control 57 M Bladder Transitional cell Liver Death
Table 2 Participants’ general characteristics
Totala
(N=20)
Nadroparina
(N=10)
Controla
(N=10)
P
valueb
Age (years) 70.0 73.5 69.0 0.520
Gender M/F 10/10 4/6 5/5 1.000
Weight (kg) 63.9 62.4 67.8 0.384
TP (%) 90.5 88 91 0.544
PTT (s) 28.1 28,1 28.1 0.744
Platelets (G/l) 234 210 248 0.450
Creatinine (μmol/l) 80 89 73 0.910
Creatinine clearance
(ml/min)
56 55 59 0.910
Duration of cancer
disease (months)
18 30 12.5 0.075
WHO performance
status
2.5 2 3 0.029
Functional
Independence
Measure (FIM) score
(max 126)
123 124 122 0.331
Mini Mental State
(MMS) score
(max 30)
28 28 29 0.517
aMedian for continuous variables and number (%) for non-continuous
variables
bP calculated with Fisher’s exact test for non-continuous values and
Mann–Whitney U test for continuous values
Table 3 Events recorded during the study
Totala
(N=20)
Nadroparina
(N=10)
Controla
(N=10)
P
valueb
DVT or PE 1 (5) 1 (10) 0 (0) 1.000
Minor
bleeding
2 (10) 0 (0) 2 (20) 0.474
Major
bleeding
1 (5) 1 (10) 0 (0) 1.000
Death 14 (70) 5 (50) 9 (90) 0.141
a Number (%)
bP calculated with Fisher’s exact test
DVT Deep venous thrombosis, PE pulmonary embolism
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As a pilot, this study provides the number needed to
perform adequate power analysis. Comparisons between
groups were made with Fischer’s exact test for binary
variables and with Mann–Whitney’s test for ordinal or
continuous variables. A survival analysis was performed
using the Kaplan–Meier life-table method. Curves were
compared using a log-rank test. Analyses were done with
Stata version 9.2 software (Stata Corporation 2005, College
Station, TX, USA). Survival data was obtained from the
central state population registry [7].
Results
Twenty patients were included over a period of 18 months.
This represented 13% of the total population of cancer
patients admitted for palliative care to our 104-bed hospital
with an estimated life expectancy of less than 6 months
(Fig. 1). Low accrual was explained by LMWH contrain-
dication, patients’ incompetence to sign informed consent
and patients’ refusal to participate in the study.
Patients’ characteristics
Age varied between 55 and 88 years with a median of
69 years in the control group and of 73.5 years in the group
receiving prophylactic nadroparin, but this was not statis-
tically different. There was only one haematology tumour
and 19 solid tumours, and all were far advanced and/or
widely metastasised cancers. Most were adeno-carcinomas,
eight in the nadroparin group and four in the control group.
Duration of cancer disease before admission was 30 months
in the nadroparin group and 12.5 months in the control
group (P=0.075). Mini Mental State [8] and Functional
Independence Measure [16] scores were comparable.
However, WHO performance status was 3 in the control
group and 2 in the group receiving prophylactic nadroparin,
and this was statistically different (P=0.029; Tables 1 and 2).
Events
VTE occurred once as both DVT and PE at the same time in
a patient receiving prophylactic nadroparin. Major bleeding
occurred once as a rectorrhagia in a patient receiving
prophylactic nadroparin, and two patients of the control
group presented minor bleeding with sputum and diarrhoea
(Table 3). No episodes of thrombocytopenia were recorded
either on days 7 and 14 as per protocol or later during the
clinical course. Six patients (33%) could be discharged home
with five of them in the group receiving prophylactic
nadroparin, but the difference was not significant.
At 3 months, there was a tendency towards more deaths
in the control group with nine patients dying, whereas five
died in the group receiving prophylactic nadroparin (P=
0.141). Two patients survived for more than 9 months in
the treated group vs 0 in the other group.
The Kaplan–Meier survival curves are shown in Fig. 2,
but there was no statistical difference between the groups
according to the log-rank test (P=0.2382).
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Treated 10 4 3 2 2 0
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Fig. 2 Kaplan–Meier survival curves according to treatment status
(dotted line, treated with nadroparin; solid line, not treated). Log-rank
test, P=0.2382. N=20
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Fig. 3 Proposition of a deci-
sional algorithm for prophylactic
LMWH administration in the
presence of risk factors for VTE
in cancer patients under pallia-
tive care
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Post hoc power analysis reveals that a Fisher’s exact test
with a 0.050 two-sided significance level will have 81 and
90% power to detect the difference between a treated group
proportion of 0.500 and a control group proportion of 0.900
when the sample size in each group reaches 23 and 29
subjects, respectively.
Discussion
Utility of prophylactic anti-coagulation in palliative care
has yet to be demonstrated. The results of our open
prospective randomised study did show neither clear benefit
for the administration of prophylactic nadroparin nor
obvious disadvantages.
More deaths occurred in the control group during the
study and may have resulted from undetected VTE. Terminal
VTE might thus have occurred, but this hypothesis couldn’t
be verified because autopsy was not performed.
Patients receiving prophylactic nadroparin had a
statistically significant better WHO performance status
at inclusion, and 50% of them could be discharged home.
Duration of cancer was longer and there were more
adenocarcinomas in the nadroparin group, but the
difference did not reach statistical significance. Taken
together though, these factors may suggest a more
indolent course of the disease explaining why a higher
level of activity was retained. In addition, mobility, as an
indication of both physical and psychological well-being,
may be a good protection factor against VTE. We would
thus encourage physical exercise in patients capable and
willing to maintain activity during the palliative phase of
cancer.
Our study included a limited number of patients
despite large inclusion criteria confirming the technical
difficulties of specific palliative-care research [1, 4, 5, 11,
18, 21]. Inability to give informed consent because of poor
general conditions at admission was the main reason for
participants’ exclusion. Given the recruitment difficulties
encountered in our specialised palliative care centre, we
would call for the design of multi-institutional collabora-
tive studies to follow on this important subject. Alterna-
tively, palliative-care cancer patients should have earlier
access to this research as this may help obtain informed
consent at a better time. Finally, the development of
supportive care leading towards smoother transition from
curative to palliative care may also be an appropriate
answer to increase scientific research in favour of this
highly vulnerable group of patients.
Practical guidelines based on other types of patients will
thus continue to influence the prescription of prophylactic
anticoagulation. In this respect, we would like to remind
that hospitalisation by itself is not an indication for
prophylactic LMWH, whereas immediate post-surgical
period and acute medical problems are [13].
It would thus appear legitimate to prescribe prophylactic
LMWH when patients’ quality of life is good enough to
indicate therapeutic anticoagulation in the case of a VTE
event (Fig. 3). When life expectancy is a matter of days or
perhaps even weeks, prophylactic anticoagulation is prob-
ably futile since most symptoms can be adequately
controlled with other means [4, 14]
Palliative care faces great challenges in front of cancer
augmentation and aging of the population [23, 29]. On the
one hand, our study would suggest absence of a clear
demonstration that the administration of prophylactic
LMWH is of benefit for advanced cancer patients hospital-
ised for palliative care. There was, though, a tendency
towards less death occurrence during hospitalization, and
two participants survived beyond expectation. Previous
results have suggested increase survival for cancer patients
with a life expectancy of more than 6 months who received
LMWH [17]. Our finding may thus contribute to extend
LMWH administration to advanced cancer patients with the
shortest life expectancy to facilitate home discharge and
optimise the utilisation of health resources.
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